Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion
Eli Lilly (LLY) is in advanced negotiations to acquire Kelonia Therapeutics in a deal valued at over $2 billion, according to The Wall Street Journal. The acquisition aims to expand Eli Lilly's cancer pipeline and is expected to be announced soon.
Tickers: $LLY
Topics: Eli Lilly Kelonia Therapeutics M&A Pharmaceutical Industry